Michel Sadelain, MD, PhD, completed his medical degree at the University of Paris, France, and completed a PhD at the University of Alberta, Canada. He carried out his clinical residency at the Centre Hospitalier Universitaire Saint-Antoine in Paris, France, and his postdoctoral fellowship at the Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, Cambridge, MA, before joining the Memorial Sloan Kettering Cancer Center, New York, NY, as an Assistant Member.
Speaking on CAR T-cells for hematological disorders
Dr Sadelain is well known for his influence and contributions to the field of CAR T-cells. He has also made major contributions to the development of stem cell therapies for hematological disorders. His work has focused on investigating novel strategies to extend the survival of CAR T-cells in the body and approaches to overcome tumor resistance to CAR T-cells. Dr Sadelain’s laboratory also studies gene transfer in hematopoietic stem cells and T-cells and the regulation of transgene expression. Dr Sadelain has authored over 150 scientific peer review papers and book chapters in these fields.